Pakistan Journal of Pharmaceutical Sciences

Abstract: Rosacea is a chronic facial inflammatory disease with a complex aetiology and pathogenesis, involving psychological, lifestyle and immune factors, and significantly impacting patients' quality of life. This study aims to use the compound glycyrrhizin combined with fractional CO2 laser treatment for rosacea patients with skin lesions and to provide a reference for improving skin lesions and strengthening skin barrier function. A total of 108 patients with rosacea skin lesions admitted to Suzhou Kowloon Hospital between January 2018 and January 2022 were randomly divided into two groups by balloting: A control group (n=54, conventional treatment) and an observation group (n=54, compound glycyrrhizin combined with fractional CO2 laser treatment). The therapy was continuously administered for 12 weeks in both groups. The improvement in skin lesions (the number of papules, pustules, acne, and nodular cysts), skin barrier function, and incidence of adverse reactions in the two groups before and after treatment were analyzed using SPSS26.0 and GraphPad Prism software (version 8.0). After treatment, the skin lesions and skin barrier function improved in both groups. The numbers of papules, pustules, acne and nodular cysts were lower in the observation group than in the control group. Percutaneous water loss and erythema decreased in the observation group, while oil secretion and epidermal water content were higher than those in the control group (P<0.05). The incidence of adverse reactions was high in the observation group; however, there was no significant difference between the groups (P>0.05). Glycyrrhizin combined with fractional CO2 laser treatment for patients with rosacea can improve the curative effect in patients, improve skin lesions, and strengthen their skin barrier function, which is worthy of promotion.